Comparison of albicans vs. non-albicans candidemia in French intensive care units

被引:37
作者
Leroy, Olivier [1 ]
Mira, Jean-Paul [2 ,3 ]
Montravers, Philippe [4 ,5 ]
Gangneux, Jean-Pierre [6 ,7 ]
Lortholary, Olivier [8 ,9 ]
机构
[1] Ctr Hosp Gustave Dron, Serv Reanimat Med & Malad Infect, F-59208 Tourcoing, France
[2] Hop Cochin, AP HP, Serv Reanimat Med, F-75014 Paris, France
[3] Univ Paris 05, INSERM, U567, F-75006 Paris, France
[4] CHU Bichat Claude Bernard, AP HP, Dept Anesthesie Reanimat, F-75018 Paris, France
[5] Univ Paris 07, F-75018 Paris, France
[6] CHU Pontchallou, Lab Parasitol Mycol, F-35000 Rennes, France
[7] Univ Rennes 1, IRSET, EA SeRAIC 4427, F-35043 Rennes, France
[8] CHU Necker Enfants Malad, AP HP, Ctr Infectiol Necker Pasteur, F-75015 Paris, France
[9] Inst Pasteur, CNRS, Ctr Natl Reference Mycol & Antifong, URA3012, F-75015 Paris, France
来源
CRITICAL CARE | 2010年 / 14卷 / 03期
关键词
ANTIFUNGAL THERAPY; RISK-FACTORS; INFECTIONS; EPIDEMIOLOGY; CANDIDIASIS; MANAGEMENT;
D O I
10.1186/cc9033
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Introduction: Candidemia raises numerous therapeutic issues for intensive care physicians. Epidemiological data that could guide the choice of initial therapy are still required. This analysis sought to compare the characteristics of intensive care unit (ICU) patients with candidemia due to non-albicans Candida species with those of ICU patients with candidemia due to Candida albicans. Methods: A prospective, observational, multicenter, French study was conducted from October 2005 to May 2006. Patients exhibiting candidemia developed during ICU stay and exclusively due either to one or more non-albicans Candida species or to C. albicans were selected. The data collected included patient characteristics on ICU admission and at the onset of candidemia. Results: Among the 136 patients analyzed, 78 (57.4%) had candidemia caused by C. albicans. These patients had earlier onset of infection (11.1 +/- 14.2 days after ICU admission vs. 17.4 +/- 17.7, p = 0.02), higher severity scores on ICU admission (SOFA: 10.4 +/- 4.7 vs. 8.6 +/- 4.6, p = 0.03; SAPS II: 57.4 +/- 22.8 vs. 48.7 +/- 15.5, P = 0.015), and were less often neutropenic (2.6% vs. 12%, p = 0.04) than patients with candidemia due to non-albicans Candida species. Conclusions: Although patients infected with Candida albicans differed from patients infected with non-albicans Candida species for a few characteristics, no clinical factor appeared pertinent enough to guide the choice of empirical antifungal therapy in ICU.
引用
收藏
页数:6
相关论文
共 17 条
[1]
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]
Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species -: art. no. 22 [J].
Cheng, MF ;
Yang, YL ;
Yao, TJ ;
Lin, CY ;
Liu, JS ;
Tang, RB ;
Yu, KW ;
Fan, YH ;
Hsieh, KS ;
Ho, M ;
Lo, HJ .
BMC INFECTIOUS DISEASES, 2005, 5 (1)
[3]
Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit [J].
Chow, Jennifer K. ;
Golan, Yoav ;
Ruthazer, Robin ;
Karchmer, Adolf W. ;
Carmeli, Yehuda ;
Lichtenberg, Deborah ;
Chawla, Varun ;
Young, Janet ;
Hadley, Susan .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (08) :1206-1213
[4]
*CLIN LAB STAND I, ANT SUSC TEST
[5]
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study [J].
Garey, Kevin W. ;
Rege, Milind ;
Pai, Manjunath P. ;
Mingo, Dana E. ;
Suda, Katie J. ;
Turpin, Robin S. ;
Bearden, David T. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) :25-31
[6]
Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units [J].
Holley, Anthony ;
Dulhunty, Joel ;
Blot, Stijn ;
Lipman, Jeffrey ;
Lobo, Suzana ;
Dancer, Craig ;
Rello, Jordi ;
Dimopoulos, George .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (06) :554.e1-554.e7
[7]
Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry [J].
Horn, David L. ;
Neofytos, Dionissios ;
Anaissie, Elias J. ;
Fishman, Jay A. ;
Steinbach, William J. ;
Olyaei, Ali J. ;
Marr, Kieren A. ;
Pfaller, Michael A. ;
Chang, Chi-Hsing ;
Webster, Karen M. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (12) :1695-1703
[8]
Invasive candidiasis in ICU: Analysis of antifungal treatments in the French study AmarCand [J].
Leroy, O. ;
Mira, J. -P. ;
Montravers, P. ;
Gangneux, J. -P. ;
Gouin, F. ;
Sollet, J. -P. ;
Carlet, J. ;
Reynes, J. ;
Rosenheim, M. ;
Regnier, B. ;
Lortholary, O. .
ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2008, 27 (12) :999-1007
[9]
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006) [J].
Leroy, Olivier ;
Gangneux, Jean-Pierre ;
Montravers, Philippe ;
Mira, Jean-Paul ;
Gouin, Francois ;
Sollet, Jean-Pierre ;
Carlet, Jean ;
Reynes, Jacques ;
Rosenheim, Michel ;
Regnier, Bernard ;
Lortholary, Olivier .
CRITICAL CARE MEDICINE, 2009, 37 (05) :1612-1618
[10]
LIPMAN J, 2009, JAMA-J AM MED ASSOC, V302, P2323